Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes

Although competing endogenous RNAs (ceRNAs) have been implicated in many solid tumors, their roles in breast cancer subtypes are not well understood. We therefore generated a ceRNA network for each subtype based on the significance of both, positive co-expression and the shared miRNAs, in the corresponding subtype miRNA dys-regulatory network, which was constructed based on negative regulations between differentially expressed miRNAs and targets. All four subtype ceRNA networks exhibited scale-free architecture and showed that the common ceRNAs were at the core of the networks. Furthermore, the common ceRNA hubs had greater connectivity than the subtype-specific hubs. Functional analysis of the common subtype ceRNA hubs highlighted factors involved in proliferation, MAPK signaling pathways and tube morphogenesis. Subtype-specific ceRNA hubs highlighted unique subtype-specific pathways, like the estrogen response and inflammatory pathways in the luminal subtypes or the factors involved in the coagulation process that participates in the basal-like subtype. Ultimately, we identified 29 critical subtype-specific ceRNA hubs that characterized the different breast cancer subtypes. Our study thus provides new insight into the common and specific subtype ceRNA interactions that define the different categories of breast cancer and enhances our understanding of the pathology underlying the different breast cancer subtypes, which can have prognostic and therapeutic implications in the future.

[1]  Jian Zhang,et al.  A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells , 2014, Tumor Biology.

[2]  Eujin Lee,et al.  Methionine sulfoxide reductase B3 deficiency inhibits cell growth through the activation of p53-p21 and p27 pathways. , 2014, Archives of biochemistry and biophysics.

[3]  Aleix Prat Aparicio Comprehensive molecular portraits of human breast tumours , 2012 .

[4]  F. Berthold,et al.  Identification of DEIN, a Novel Gene with High Expression Levels in Stage IVS Neuroblastoma , 2007, Molecular Cancer Research.

[5]  W. Woodward,et al.  MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. , 2016, International journal of radiation oncology, biology, physics.

[6]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[7]  Debra L Winkeljohn Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[8]  J.,et al.  The New England Journal of Medicine , 2012 .

[9]  Bing Shi,et al.  TAM: A method for enrichment and depletion analysis of a microRNA category in a list of microRNAs , 2010, BMC Bioinformatics.

[10]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[11]  Z. Culig Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. , 2014, European urology.

[12]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[13]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[14]  Adam A. Margolin,et al.  Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas , 2013, Nature Genetics.

[15]  J. Slingerland,et al.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.

[16]  Frank Berthold,et al.  Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma , 2009, BMC Molecular Biology.

[17]  Ning Liu,et al.  Systematic analysis of lncRNA–miRNA–mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer , 2018, Journal of Translational Medicine.

[18]  Christian Gieger,et al.  A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization , 2006, Nature Genetics.

[19]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Tao Xi,et al.  STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer , 2016, Oncotarget.

[21]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[22]  V. Gebski,et al.  Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Esteller Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[24]  E. Andrechek,et al.  A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer , 2013, Breast Cancer Research.

[25]  Jason I. Herschkowitz,et al.  Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts , 2013, Genome Biology.

[26]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[27]  Martin Reczko,et al.  DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs , 2012, Nucleic Acids Res..

[28]  Goberdhan P Dimri,et al.  A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells , 2016, Oncotarget.

[29]  S. Oesterreich,et al.  Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression. , 2016, Cancer research.

[30]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Xia Li,et al.  Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes. , 2014, Human molecular genetics.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[33]  M. Dowsett,et al.  Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease , 2016, Clinical Cancer Research.

[34]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[35]  R. Bellazzi,et al.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Fernö,et al.  Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up , 2010, Breast Cancer Research and Treatment.

[37]  E. Izaurralde,et al.  Towards a molecular understanding of microRNA-mediated gene silencing , 2015, Nature Reviews Genetics.

[38]  Y. Miki,et al.  Periostin suppression induces decorin secretion leading to reduced breast cancer cell motility and invasion , 2014, Scientific Reports.

[39]  Tingting Shao,et al.  The mRNA related ceRNA–ceRNA landscape and significance across 20 major cancer types , 2015, Nucleic acids research.

[40]  Jinpeng Rao,et al.  Construction of implantation failure related lncRNA-mRNA network and identification of lncRNA biomarkers for predicting endometrial receptivity , 2018, International journal of biological sciences.

[41]  B. Xiao,et al.  [Differences in expression profiles of circular RNA between luminal breast cancer cells and normal breast cells]. , 2018, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[42]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[43]  Paul L. Roebuck,et al.  TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. , 2015, Cancer research.

[44]  Junxia Chen,et al.  Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma , 2016, Oncotarget.

[45]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[46]  References , 1971 .

[47]  X. Cui,et al.  LncRNA‐Hh Strengthen Cancer Stem Cells Generation in Twist‐Positive Breast Cancer via Activation of Hedgehog Signaling Pathway , 2015, Stem cells.

[48]  N. Campbell Genetic association database , 2004, Nature Reviews Genetics.

[49]  Stefan Wuchty,et al.  Peeling the yeast protein network , 2005, Proteomics.

[50]  A. Chinnaiyan,et al.  The emergence of lncRNAs in cancer biology. , 2011, Cancer discovery.

[51]  C. Perou,et al.  Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch , 2011, Proceedings of the National Academy of Sciences.

[52]  Panayiotis Tsanakas,et al.  DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts , 2015, Nucleic Acids Res..

[53]  P. Brown,et al.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. , 2014, The Lancet. Oncology.

[54]  Kouhei Akazawa,et al.  Programs for calculating the statistical powers of detecting susceptibility genes in case–control studies based on multistage designs , 2009, Bioinform..

[55]  Daniel Birnbaum,et al.  Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.

[56]  E. Davidson Emerging properties of animal gene regulatory networks , 2010, Nature.

[57]  P. Reitsma,et al.  Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner , 2013, Proceedings of the National Academy of Sciences.

[58]  M. Hou,et al.  MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7. , 2016, American journal of cancer research.

[59]  J. Forbes,et al.  Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer , 2014, BMC Cancer.

[60]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.